Ultrafast ultrasound biomarkers to track Duchenne and Becker muscular dystrophy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will compare muscle ultrasound measurements in ambulatory and non-ambulatory males with Duchenne or Becker muscular dystrophy to those of healthy age-matched peers over 12 months. The ultrafast ultrasound method simultaneously assesses muscle structure, mechanics, and physiology, including stiffness, anisotropy, viscosity, fat content, volume, and microvascular flow. The goal is to identify objective, sensitive markers of disease progression that could serve as outcome measures in future trials. The study will relate imaging-derived muscle changes to everyday functional performance such as walking and strength.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Inclusion Criteria for patients with Duchenne Muscular Dystrophy: Ambulatory and non-ambulatory males (ages 5-30 at baseline testing) previously diagnosed with Duchenne Muscular Dystrophy based on absence of dystrophin expression.
* Inclusion Criteria for patients with Becker Muscular Dystrophy: Ambulatory and non-ambulatory males (ages 5-60 at baseline testing) previously diagnosed with Becker Muscular Dystrophy based on genetically confirmed, reduced or dysfunctional dystrophin.
* Inclusion Criteria for Aged-matched controls: Ambulatory males (ages 5-60 years) without disease or injury to the lower and/or upper extremities

Exclusion Criteria:

* Exclusion Criteria for patients with Duchenne and Becker Muscular Dystrophies:

Inability to undergo static exam, missing measurement site (resection/amputation), neurocognitive impairment preventing informed consent

* Exclusion Criteria for Age-matched controls: Any condition affecting muscle metabolism/function, neuromuscular disease, or injury to the lower and/or upper extremities in the past 5 years

Where it's running

• CHU de Nantes
  Nantes, France Recruiting

Study contacts

• Study coordinator: Yann PEREON
• Email: yann.pereon@chu-nantes.fr
• Phone: 0240083704

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GNT0004 gene therapy for Duchenne muscular dystrophy in ambulant boys

  This study tests a one-time IV gene therapy (GNT0004) to see if it slows DMD progression in ambulant boys aged 6–10.

  Recruiting at 10 sites Phase 2/3 Genethon · Brussels and 13 other locations · NCT07856329

• Modeling heart failure in Duchenne and Becker muscular dystrophy to find surrogate heart measures

  This study will look at heart disease in people with Duchenne/Becker muscular dystrophy and carriers to see if MRI-based heart measures can predict death or major heart problems.

  Recruiting at 9 sites Vanderbilt University Medical Center · Sacramento, California and 8 other locations · NCT07674758

• Duchenne/Becker Muscular Dystrophy EHR Data Linkage

  This study tests whether consented patients’ electronic health records can be linked with the Duchenne Registry data to create a richer view of Duchenne and Becker muscular dystrophy care.

  Recruiting at 11 sites The Duchenne Registry · Little Rock, Arkansas and 10 other locations · NCT07609394

• AOC 1044 in Duchenne Muscular Dystrophy with Exon 44 Skipping

  This study tests whether intravenous AOC 1044 helps boys with Duchenne muscular dystrophy caused by mutations amenable to exon 44 skipping.

  Recruiting at 20 sites Phase 3 Avidity Biosciences, Inc. · Westmead, New South Wales and 19 other locations · NCT07587242

• DMD gene changes and heart function in boys and young men with dystrophinopathies

  This study will test whether specific DMD gene changes and routine heart tests (blood biomarkers, ECG, and echocardiography) can help identify early heart problems in boys and young men aged 2–24 with genetically confirmed dystrophinopathies.

  Recruiting Aristotle University Of Thessaloniki · Thessaloniki · NCT07515235

• Duchenne/Becker Muscular Dystrophy Registry for patients and carriers

  This registry tests whether patients with Duchenne or Becker muscular dystrophy, or symptomatic female carriers, can be enrolled and followed across specialist centers to improve data sharing and care.

  Recruiting at 19 sites University Hospital Heidelberg · Graz and 29 other locations · NCT07402122

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.